Medigene
€1.82
1
+€0+0% Monday 07:37
Statistiche
In rialzo oggi
1.82
In ribasso oggi
1.82
In rialzo da 52 settimane
2.25
In ribasso da 52 settimane
1.39
Volume
1
Volume medio
128
Cap. di mercato
449,394
Rapporto P/E
-
Rendimento da dividendi
-
Dividendo
-
Prossimamente
Guadagni
14AugAtteso
EPS attesi
-0.5446430976000001
EPS effettivi
-0.5057400192
Le persone seguono anche
Questo elenco si basa sulle watchlist delle persone su Stock Events che seguono 0QGJ.LSE. Non rappresenta una raccomandazione d'investimento.
Concorrenti
Questo elenco è un'analisi basata su recenti eventi di mercato. Non è una raccomandazione di investimento.
Adaptimmune Therapeutics
ADAP
Cap. di mercato324.8M
Immatics N.V
IMTX
Cap. di mercato1.14B
Gilead Sciences
GILD
Cap. di mercato98.35B
Bluebird bio
BLUE
Cap. di mercato108.22M
Novartis
NVS
Cap. di mercato244.75B
Allogene Therapeutics
ALLO
Cap. di mercato549.96M
Precigen
PGEN
Cap. di mercato316.49M
Info
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Show more...
CEO
Dr. Dolores J. Schendel
Dipendenti
58
Paese
DE
ISIN
DE000A40ESG2